In recent years there has been an upsurge of new biologics and small-molecule therapies for ulcerative colitis (UC), making it challenging for the UC interdisciplinary care team (such as gastroenterologists, physician associates, and nurse practitioners) to stay abreast of these advances and navigate the complexity of treatment decisions. Treatment selection must now include consideration of many patient and disease factors, and within a shared decision-making (SDM) model. Given the ongoing burden associated with UC and its comorbidities, including isolated proctitis (IP), it is essential that gastroenterologists be able to manage UC effectively with optimal utilization of available agents. In this CME Outfitters Infographic, expert faculty will explore the role of new advanced therapies in UC treatment algorithms, facilitating the transition to these therapies in patients with UC who are non-/under-responsive to traditional treatments, and utilizing traditional treatments as well as available biologics and small-molecule therapies to optimize outcomes in patients with IP.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com/activity/deciphering-ulcerative-colitis-clinical-clues-for-treatment-selection-switching-and-disease-optimization/
- Start Date: 2024-12-27 06:00:00
- End Date: 2024-12-27 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Pfizer (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Gastroenterology